Free Trial

Arvinas (ARVN) Stock Price, News & Analysis

$34.54
-1.41 (-3.92%)
(As of 10:34 AM ET)
Today's Range
$34.21
$36.16
50-Day Range
$31.36
$44.85
52-Week Range
$13.57
$53.08
Volume
89,836 shs
Average Volume
718,880 shs
Market Capitalization
$2.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.13

Arvinas MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
70.1% Upside
$61.13 Price Target
Short Interest
Bearish
12.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Arvinas in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$404,489 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.00) to ($4.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

Medical Sector

376th out of 920 stocks

Pharmaceutical Preparations Industry

163rd out of 425 stocks

ARVN stock logo

About Arvinas Stock (NASDAQ:ARVN)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ARVN Stock Price History

ARVN Stock News Headlines

Arvinas (NASDAQ:ARVN) Earns Buy Rating from HC Wainwright
Arvinas appoints new chief business officer
Arvinas, Inc. (ARVN)
Arvinas gets new chief medical officer
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/23/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
445
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.13
High Stock Price Target
$90.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+70.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

Net Income
$-367,300,000.00
Net Margins
-185.09%
Pretax Margin
-493.69%

Debt

Sales & Book Value

Annual Sales
$78.50 million
Book Value
$8.91 per share

Miscellaneous

Free Float
64,853,000
Market Cap
$2.46 billion
Optionable
Optionable
Beta
1.95
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 64)
    Chairperson, CEO & President
    Comp: $1.08M
  • Dr. Ian Taylor Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Randy Teel Ph.D. (Age 44)
    Interim CFO & Treasurer
  • Mr. David K. Loomis M.B.A. (Age 50)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    Vice President of Investor Relations
  • Mr. Jared M. Freedberg J.D. (Age 55)
    General Counsel & Corporate Secretary
  • Mr. Steve Weiss (Age 54)
    Senior VP & Chief Human Resources Officer
  • Dr. John A. Grosso Ph.D. (Age 67)
    Senior Vice President of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 56)
    Senior Vice President of Neuroscience & Platform Biology
  • Mr. John P. Northcott (Age 46)
    Chief Commercial Officer

ARVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price target for 2024?

16 brokerages have issued 12-month price targets for Arvinas' stock. Their ARVN share price targets range from $20.00 to $90.00. On average, they predict the company's stock price to reach $61.13 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2024?

Arvinas' stock was trading at $41.16 at the beginning of 2024. Since then, ARVN stock has decreased by 12.7% and is now trading at $35.95.
View the best growth stocks for 2024 here
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.45. The business had revenue of $25.30 million for the quarter, compared to analyst estimates of $32.94 million. Arvinas had a negative trailing twelve-month return on equity of 64.79% and a negative net margin of 185.09%. Arvinas's revenue was down 22.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.54) earnings per share.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.22%), Price T Rowe Associates Inc. MD (6.38%), Bellevue Group AG (3.49%), Nordea Investment Management AB (0.40%), Wasatch Advisors LP (0.30%) and BNP Paribas Financial Markets (0.22%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARVN) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners